Manufacture and quality control of CAMPATH-1 antibodies for clinical trials

Author： Phillips J Drumm A Harrison P Bird P Bhamra K Berrie E Hale G

ISSN： 1465-3249

Source： Cytotherapy, Vol.3, Iss.3, 2001-05, pp. : 233-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CAMPATH-1 antibodies in stem-cell transplantation

By Hale G Cobbold S Novitzky N Bunjes D Willemze R Prentice HG Milligan D MacKinnon S Waldmann H

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 145-164

Ashgate Publishing Ltd

Access to resources Recommend Favorite

The CD52 antigen and development of the CAMPATH antibodies

By Hale G

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 137-143

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Pharmacokinetics of CAMPATH-1H in BMT patients

By Rebello P Cwynarski K Varughese M Eades A Apperley JF Hale G

Cytotherapy, Vol. 3, Iss. 4, 2001-07 ,pp. : 261-267

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CAMPATH-1H in the treatment of autoimmune cytopenias

By Marsh JCW Gordon-Smith EC

Cytotherapy, Vol. 3, Iss. 3, 2001-05 ,pp. : 189-195

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Impact on T-cell depletion and CD34⁺ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G

By Williams R.J. Clarke E. Blair A. Evely R. Hale G. Waldmann H. Brookes S. Pamphilon D.H.

Cytotherapy, Vol. 2, Iss. 1, 2000-01 ,pp. : 5-14

Ashgate Publishing Ltd

Access to resources Recommend Favorite